Since we re-initiated coverage on GT Biopharma (GTBP), we’ve seen some of the biggest events announced in the company’s history, in our opinion. During this time, the company also continued to add to its team of industry veterans and biopharma professionals.
Some of the biggest runs we’ve seen so far have been within the last few months and as far as the last 60 days have been concerned, GT Biopharma has held one of its most consistent uptrends in recent months:
In between the end of May and the beginning of September, we’ve watched as GT Biopharma (GTBP) has gone on several clear breakouts in attempts to break past its upper resistance levels set on the chart.
On numerous occasions, GTBP has run up by nearly 100% within the matter of a few weeks. In fact, not counting the 1-2 day rallies of 5-10%, since June 4 there has been a number of moves as you’ll see on the chart.
But what has happened recently could be setting a new tone. Look at the chart above. From late May to early June GTBP went on a strong 66% rally but as you can see, during the period to follow we saw GTBP quickly pull back to its previous “May levels”.
The more recent “big breakout” is what could be the new tone-setter. Take a look at the jump that GTBP saw from $1.49 on July 5 to highs of $2.80 on July 25. This was certainly a strong move but the resulting pullback was not as abrupt AND since pulling back, GTBP has managed to hold a steady uptrend ever since…the support didn’t reset back to “May levels”.
We feel that the reason “why” has much to do with the activity GTBP has seen over the last few weeks with a lot of the attention being placed on new events:
The company announced a Material Transfer Agreement between a “Major Pharmaceutical Company” and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. Under the terms of the agreement, this unnamed, “Major Pharmaceutical Company” will supply a formulation of their “multibillion-dollar, widely prescribed oncology drug,” which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.
On this day we found out that the company would be undertaking the actual initiation of a combination trial of OXS-1550 and a multi-billion dollar oncology drug, owned by a major Pharmaceutical Company. This time we found out the generic name for the drug: ibrutinib. This was revealed from Dr. Vallera’s comments on the latest developments:
Dr. Daniel Vallera said: “Based on our exciting preliminary in vitro experiments, the initial preclinical work suggests a much greater effect when OXS-1550 is given with this drug. We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor, which is already an established chemotherapeutic agent. We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment.”
What is the multi-billion dollar oncology drug?
It’s called ibrutinib, which was developed by Pharmacyclics up to Phase II, then partnered with Johnson & Johnson…but what could be the biggest piece of information with this drug is that Pharmacyclics was acquired by AbbVie who just reported 2017 net sales of ibrutinib of $2.573 Billion. Think about what this could mean for GT Biopharma!
Recent Industry Developments Shed Bright Light On GTBP’s Novel Therapy
The collaboration with a $96M upfront with $5B in milestone/royalty payments announced on August 27th between a small cap biotech company and Roche/Genentech not only provides validation of NK cell treatment but more specifically of the NK cell – engager concept.
GTBP’s CEO Dr. Raymond Urbanski stated it best:
Urbanski continued, “Although there are many similarities between Affimed and GT Biopharma, there are significant differences. Both platforms utilize fusion proteins with one end binding to NK cells and the other targeting a tumor antigen. Significant differences in the platforms reside in the way the proteins are constructed and how they address the NK activation and proliferation issue. Like first-generation CAR-T, without a specific stimulatory agent, the cells become exhausted as their numbers dwindle. GT Biopharma’s innovative NK cell-engager platform incorporates IL-15, a potent activator, and proliferator of NK cells. No other, including Affimed’s, NK cell technology has this.”
This could be a reason why so many people are beginning to pay closer attention to GTBP. Do the numbers speak for themselves? In our opinion, these figures are hard to ignore. Furthermore, these last few weeks of trading have been some of the most active since GTBP was trading north of the $4 mark.
GTBP & Looking Ahead
Looking ahead into the days and months to come, we feel that GT Biopharma (GTBP) could be at a tipping point with the market echoing a strong sentiment after this recent flurry of big news. Meanwhile, we see that the company has a hot pipeline of multiple therapies in different stages along with a continual flow of industry experience coming on board.
Click Here For More & A Full Report On GT Biopharma (GTBP)
Disclaimer: Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC, and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018, and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
